GBI Research, Nov 2011, Pages: 216
centralnervoussystem disorders which are Alzheimer’s disease, Depression, Epilepsy, Parkinson’s disease and Schizophrenia. The classification of five major centralnervoussystemdiseases is done
AM Mind Power Solutions, April 2011, Pages: 37
in 2009. - The AD market could cross USD9.0 billion by 2016 with the introduction of disease-modifying drugs (DMDs). AD is likely to be the primary driver of growth in the larger centralnervoussystem
John Wiley and Sons Ltd, Jan 2010, Pages: 276
Advances in biomarker development are revolutionizing the way we study, diagnose and treat disease. However, progress in the development and use of biomarkers for diseases of the centralnervous
Elsevier Science and Technology, Dec 2011, Pages: 1120
, and development of the nervoussystem. Later chapters cover cell injury and inflammation, neurodegenerative diseases, sensory transduction, and neural processing/behavior. By understanding mechanisms
Greystone Associates, June 2011
associated with longevity and aging, and significant increases in the number of children diagnosed with autism. Because diseases of the centralnervoussystem often result in compromised cognitive and/or motor
GBI Research, Sep 2011, Pages: 97
“Clinical Trial Recruitment in CentralNervousSystem Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia” gives a robust idea about the patient recruitment
Sheila Greco Associates, May 2011, Pages: 1
EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the centralnervoussystem
Greystone Associates, Aug 2011
market activity are derived using standard modeling and statistical techniques. Extended Release CentralNervousSystem Therapeutics Drugs, Indications, Markets and Prospects
Decision Resources, Inc., April 2010, Pages: 35
and neurology R&D; insights on the Alzheimer’s disease market from Matthew Winton, Ph.D., a Decision Resources analyst specializing in centralnervoussystemdiseases.
- Primary data: Results from a survey of 29
GBI Research, Nov 2011, Pages: 230
CentralNervousSystem Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
Summary
GBI
Sheila Greco Associates, May 2011, Pages: 1
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of centralnervoussystemdiseases and disorders
Sheila Greco Associates, May 2011, Pages: 2
Lundbeck is an international pharmaceutical company highly committed to improve the quality of life for people suffering from centralnervoussystem (CNS) disorders. For this purpose Lundbeck
Research Facts Ltd, May 2009, Pages: 66
forward to 8% annual growth.
There are many drug delivery technology companies worldwide. This report profiles the Top 35 with technologies for delivery to the centralnervoussystem
Frost & Sullivan, March 2009, Pages: 58
in this research: cardiovascular diseases, centralnervoussystem disorders, ophthalmology, women’s health, and urology.
This research service provides a strategic analysis of the European specialty pharma market and includes
Jain PharmaBiotech, Feb 2012, Pages: 628
This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervoussystem as well as in chronic diseases such as neurodegenerative disorders because many
Elsevier Science and Technology, June 2009, Pages: 628
include Parkinson's and Alzheimer's, but even more common are problems of aging which are not due to disease but to more subtle impairments in neurobiological systems, including impairments in vision
